Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28751899 | 0.79 | STK17B (0.51) | BRD4STK17BSTK17A | |
| SCHEMBL22934332 | 0.79 | STK17B (0.51) | BRD4STK17BSTK17A | |
| SCHEMBL29406468 | 0.79 | STK17B (0.51) | BRD4STK17BSTK17A | |
| SCHEMBL28751942 | 0.78 | STK17B (0.50) | BRD4STK17BSTK17A | |
| SCHEMBL28752003 | 0.78 | STK17B (0.50) | BRD4STK17BSTK17A | |
| SCHEMBL22931747 | 0.78 | CXCR1 (0.34) | BRD4STK17BSTK17A | |
| SCHEMBL28751938 | 0.78 | CXCR1 (0.34) | BRD4STK17BSTK17A | |
| SCHEMBL28941703 | 0.71 | STK17B (0.51) | BRD4STK17BSTK17A | |
| SCHEMBL27175710 | 0.70 | STK17B (0.52) | BRD4STK17BSTK17A | |
| SCHEMBL6760169 | 0.70 | KDM4E (0.40) | STK17BSTK17ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939343-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4007758-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | Mersana Therapeutics, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114585623-A | Bis [ N- ((5-carbamoyl) -1H-benzo [ d ] imidazol-2-yl) pyrazole-5-carboxamide ] derivatives and related compounds as STING (interferon gene stimulator) agonists for the treatment of cancer | 梅尔莎纳医疗公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939343-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | BRD4 1562/4885STK17B 1154/4885STK17A 1045/4885 |
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | BRD4 1562/4885STK17B 1154/4885STK17A 1045/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | BRD4 1562/4885STK17B 1154/4885STK17A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.